Myriad Genetics (NASDAQ:MYGN) Earns Hold Rating from Analysts at StockNews.com
StockNews.com assumed coverage on shares of Myriad Genetics (NASDAQ:MYGN – Free Report) in a research report report published on Thursday morning. The brokerage issued a hold rating on the stock. Several other equities analysts also recently weighed in on the company. The Goldman Sachs Group increased their target price on Myriad Genetics from $25.00 to […]